spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

David Hirsh


 

Editorial 

Emma Naks
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
RESEARCH AND DEVELOPMENT
Advanced Therapy Medicinal Products

Coming of Age


Despite slow progress, Gopalan Narayanan of the NDA Group believes the future is bright for cell- and gene-based therapies. Due to their potential in curing or correcting disease pathology, the industry should see increased uptake across the field, with more products gaining approval.
BIO-SECURITY
Bioterrorism

The Lone Wolf


Miri Halperin Wernli at Actelion Pharmaceuticals and Boaz Ganor at the International Institute for Counter-Terrorism urge biopharma firms to remain vigilant against potential intrusions. With employee and patient safety at stake, companies cannot afford to neglect any data access gaps or security deficiencies.
  Legal, Regulatory and Public Policy
Clinical Trial Agreements

Standard Practice


As overheads rise, Richard Dickinson, Blaine Templeman and Jackie Mulryne from Arnold & Porter LLP propose implementing more simplistic and standardised approaches to documentation, which will improve the cost and timing of clinical trial contracting.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October
Banner of TwistDX on Samedan
Banner of Biopharmaspec Ltd on Samedan
Banner of BioProcess International on Samedan
 
Industry Events

Biotech China

3-5 September 2015, Nanjing International Expo Centre, Nanjing, China

BIOTECH CHINAis China's must-attend bio pharmaceutical exhibition. Numbers of exhibitors, authoritative medical seminar and high media attention make BIOTECH CHINA the most authoritative and professional exposition.
More info >>

 
News and Press Releases

Capsugel Investing More Than $25 Million in Increased Production Capacity and Quality Enhancements for its Industry-Leading Vegetarian Capsule Portfolio

Morristown, N.J., March 26, 2015 – Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its industry-leading vegetarian capsules. The investment is enabling a combination of new production lines and technology upgrades at four manufacturing locations in Capsugel’s global network: Greenwood, South Carolina, U.S.; Puebla, Mexico; Colmar, France; and Sagamihara, Japan. These investments began in late 2014, and the majority of the funding is taking place in 2015.
More info >>

air transport logo

 

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement